| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Yuan Xu is Director at FATE and has filed Form 4s across 2 companies. Yuan Xu's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $18K at current prices.
Historically, Yuan Xu's trades have earned a middling insider score of 64/100 across 3 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +27.5%.
The biggest single holding is FATE (~$18K) as Director. The FATE filings lean toward selling, a net 4,725 shares.
Yuan Xu has 16 Form 4 filings on record from August 2021 to June 2026, across 3 companies: Director at Fate Therapeutics (FATE), 2021–2026; Director at Xilio Therapeutics (XLO), 2022–2026; Director at AKRO, 2025.
The 23 reported transactions were 12 option or other derivative awards, 6 dispositions back to the company, 3 open-market sales and 2 stock awards.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $24K.
The largest open-market sale was 3,460 shares of FATE at an average $5.58 on June 14, 2023, about $19K. Twelve months later FATE was down 31%.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2024 | FATE Fate Therapeutics Inc | Director | Sell10b5-1 | 633 | $4.23 | $2,677.59 | -6.8% | -35.7% | -75.8% | |
| Aug 4, 2023 | FATE Fate Therapeutics Inc | Director | Sell10b5-1 | 632 | $3.71 | $2,344.72 | -6.4% | -40.8% | +24.1% | |
| Jun 14, 2023 | FATE Fate Therapeutics Inc | Director | Sell10b5-1 | 3,460 | $5.58 | $19,306.80 | -25.8% | -53.2% | -30.8% |